Difference between revisions of "Team:Bordeaux/Description"
Line 168: | Line 168: | ||
<p class="reference" align="left"> [8] (1996) Bioproducts: bio-concrete. BioIndustry 13:56–57</p> | <p class="reference" align="left"> [8] (1996) Bioproducts: bio-concrete. BioIndustry 13:56–57</p> | ||
<p class="reference" align="left"> [9] Harada T (1992) The story of research into curdlan and the bacteria producing it. Trends Glycosci Glycotechnol 4:309–317</p> | <p class="reference" align="left"> [9] Harada T (1992) The story of research into curdlan and the bacteria producing it. Trends Glycosci Glycotechnol 4:309–317</p> | ||
− | <p class="reference" align="left"> [10] Kanke M, Tanabe E, | + | <p class="reference" align="left"> [10] Kanke M, Tanabe E,(1995) Application of curdlan to controlled drug delivery. III. Drug release from sustained release suppositories in vitro. BiolPharm Bull 18:1154–1158</p> |
<p class="reference" align="left"> [11] Janeway CA, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216</p> | <p class="reference" align="left"> [11] Janeway CA, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216</p> | ||
Revision as of 08:01, 15 August 2015